Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil Sells 8,000 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the sale, the chief operating officer now directly owns 154,931 shares in the company, valued at approximately $11,351,794.37. The trade was a 4.91 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Jim Wassil also recently made the following trade(s):

• On Monday, February 3rd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $86.22, for a total transaction of $689,760.00.
• On Thursday, January 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $83.66, for a total transaction of $669,280.00.

Vaxcyte Trading Down 1.3 %

NASDAQ PCVX traded down $0.92 on Monday, reaching $72.10. 1,193,584 shares of the stock were exchanged, compared to its average volume of 1,157,385. Vaxcyte, Inc. has a one year low of $58.10 and a one year high of $121.06. The firm has a market capitalization of $9.28 billion, a PE ratio of -15.67 and a beta of 0.98. The company’s 50-day simple moving average is $84.30 and its two-hundred day simple moving average is $94.91.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.14. Sell-side analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a report on Wednesday, February 26th. The Goldman Sachs Group began coverage on shares of Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 price objective on the stock. Guggenheim reissued a “buy” rating and issued a $160.00 price objective on shares of Vaxcyte in a report on Wednesday, February 26th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vaxcyte currently has a consensus rating of “Buy” and a consensus price target of $147.50.

Institutional Investors Weigh In On Vaxcyte

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Vaxcyte during the fourth quarter valued at approximately $8,487,000. Forum Financial Management LP bought a new stake in shares of Vaxcyte during the fourth quarter valued at approximately $255,000. GF Fund Management CO. LTD. bought a new stake in shares of Vaxcyte during the fourth quarter valued at approximately $214,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Vaxcyte by 15.8% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 472,964 shares of the company’s stock valued at $38,717,000 after buying an additional 64,690 shares during the last quarter. Finally, Windsor Advisory Group LLC increased its position in Vaxcyte by 72.5% in the fourth quarter. Windsor Advisory Group LLC now owns 39,223 shares of the company’s stock worth $3,211,000 after purchasing an additional 16,479 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.